Nectar Life Sciences has introduced its first physical clinic, the Nectar Allergy Center in New York, expanding from its virtual care platform. The company, which offers at-home allergy testing, provides customized treatment plans through licensed physicians. Plans include broader allergy coverage and the addition of allergists to the team. Nectar secured $16.5 million in Series A funding, adding to its $8 million seed funding. The move aligns with the growing trend of at-home allergy testing, with competitors like Everly Health and Wyndly in the sector.
Nectar Life Sciences, a company specializing in allergy testing and treatment, has unveiled its inaugural physical clinic, the Nectar Allergy Center in New York. This move marks an expansion of its virtual care platform into a hybrid model, complementing its existing offerings. Nectar, which was introduced earlier this year, provides convenient at-home testing kits. These kits enable individuals to conduct self-tests for both indoor and outdoor allergies, with the samples then being sent to Nectar for analysis.
Following the testing phase, individuals can engage with licensed physicians through the Nectar platform. These medical professionals provide a unique, patent-pending treatment plan that includes sublingual drops. These drops are designed to target specific allergies and assist the immune system in building tolerance to the allergen over time.
The company’s recent announcement outlines its plans to broaden its services to encompass a wider range of allergic conditions, including food allergies, eczema, and asthma. To enhance its leadership team, Nectar is enlisting additional allergists. Dr. Shyam Joshi is set to join as Chief Scientific Officer, Dr. Tania Elliott as Chief Medical Officer, and Dr. Akansha Ganju as the Medical Director of the Nectar Allergy Center.
Dr. Kenneth Chahine, Nectar’s Co-founder and CEO, expressed the significance of opening this clinic, viewing it as a pivotal step toward realizing their goal of making revolutionary allergy care easily accessible. He emphasized their commitment to leveraging science and technology to alleviate the struggles faced by many individuals, particularly during the upcoming fall allergy season.
In terms of the larger industry trend, Nectar secured substantial funding with a Series A investment of $16.5 million in December, following a previous seed funding round of $8 million. This influx of capital brought the total funding raised by the company to over $24 million. Noteworthy players in the at-home allergy testing sector include Everly Health, the parent company of EverlyWell, and startup Wyndly, based in Denver, which obtained $2 million in funding earlier this year.
